Network pharmacology and computational-based approaches to activate NRF2 pathway via KEAP1 and GSK-3β inhibition: Exploring the possible molecular insights of mangiferin for Alzheimer's

Key Points

• Activation of the nrf2 pathway may offer neuroprotective benefits for Alzheimer's patients, indicating promising therapeutic avenues.
• Significant inhibition of keap1 and gsk-3β was observed, hinting at a dual mechanism for enhancing nrf2 activity.
• Analysis employing network pharmacology and computational methods elucidates the molecular workings of mangiferin in this context.
• These findings support the need for future studies to explore mangiferin's benefits in Alzheimer's, though further clinical validations are necessary.